Adolor Corporation to Present at the William Blair & Company 2011 Life Sciences Conference

EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM: ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the William Blair & Company 2011 Life Sciences Conference on Wednesday, September 7, 2011, at 2:00 P.M. Eastern Daylight Time. The conference is being held at the InterContinental New York Barclay Hotel in New York, NY.

Adolor’s presentation will be webcast live on the investor relations section of the Company’s website and will be archived for one week following the broadcast. To access the webcast, log onto the Company’s website at www.adolor.com and click on “Investor Insights,” then “Webcast.” Click on the link and follow the prompts for registration and access.

About Adolor

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.® Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com.

The Company's lead development program compound is ADL5945, a novel mu opioid receptor antagonist being developed for chronic OIC that demonstrated positive results in Phase 2 trials. The Company also has several earlier-stage compounds under development for the management of pain and CNS disorders.

For more information, visit www.adolor.com.



CONTACT:

Adolor Corporation
Stephen W. Webster, 484-595-1500

KEYWORDS:   United States  North America  New York  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.